Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim reports ‘effective treatment option’ for HIV patients

Boehringer Ingelheim reports ‘effective treatment option’ for HIV patients

9th October 2007

Boehringer Ingelheim has reported that its recently-approved therapy Aptivus (tipranavir) in combination with ritonavir (Aptivus/r) could provide HIV patients with a new treatment option for the disease.

The compound was last week awarded full approval from the US Food and Drug Administration, following from the accelerated approval granted from the body in June 2005.

Approval of the drug followed 48-week analyses of the pivotal phase III Resist studies, which showed that 33.8 per cent of patients treated with Aptivus/r showed a treatment response compared to 14.9 per cent of those administered with a CPI/r.

The compound is indicated as a combination antiretroviral treatment for treatment-experienced adult patients infected with HIV-1 strains that have shown resistance to more than one protease inhibitor.

Daniel Kuritzkes, associate professor of medicine at Harvard Medical School, said: ” Data [shows] that Aptivus/r may provide treatment-experienced HIV patients with an effective treatment option through nearly one year of therapy.”

He added that there now exists safety data for long-term treatment for examination by doctors and patients.

In May 2007, Boehringer Ingelheim announced the initiation of an international HIV/Aids study comparing the efficacy and safety of Viramune (nevirapine) with atazanir/ritonavir.

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.